GSK Wellbutrin Metabolite, Advair Successor In Phase II; NDAs In 2006-2008
Executive Summary
GlaxoSmithKline expects to bring a Wellbutrin (bupropion) metabolite into Phase III studies for major depressive disorder during the second half of 2004
You may also be interested in...
Formularies Should Stress Rx Compliance, Not Co-Pays, Pitney Bowes Says
Covering chronic disease medications as tier one to encourage patient compliance can help manage health care costs, Pitney Bowes Manager-Employee Benefits Design & Development Christine Berman said
GSK Near-Term Pipeline Relies On Line Extensions; “Wall” Of NMEs To Come
GlaxoSmithKline is relying primarily on line extensions and supplemental indications to fill its nearer-term pipeline before the effect of a revamped R&D effort kicks in
Formularies Should Stress Rx Compliance, Not Co-Pays, Pitney Bowes Says
Covering chronic disease medications as tier one to encourage patient compliance can help manage health care costs, Pitney Bowes Manager-Employee Benefits Design & Development Christine Berman said